$186.57
0.21% day before yesterday
NYSE, Nov 07, 10:04 pm CET
ISIN
US4781601046
Symbol
JNJ

Johnson & Johnson Stock price

$186.57
-2.32 1.23% 1M
+29.27 18.61% 6M
+41.95 29.01% YTD
+29.84 19.04% 1Y
+13.59 7.86% 3Y
+40.49 27.72% 5Y
+85.73 85.02% 10Y
+125.14 203.71% 20Y
NYSE, Closing price Fri, Nov 07 2025
-0.40 0.21%

New AI Insights on Johnson & Johnson Insights AI Insights on Johnson & Johnson

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$449.5b
Enterprise Value
$476.7b
Net debt
$27.2b
Cash
$18.6b
Shares outstanding
2.4b
Valuation (TTM | estimate)
P/E
18.0 | 17.0
P/S
4.9 | 4.7
EV/Sales
5.2 | 5.0
EV/FCF
24.3
P/B
5.7
Dividends
DPS
$5.14
Yield 1Y | 5Y
2.8% | 2.9%
Growth 1Y | 5Y
4.7% | 5.3%
Payout 1Y | 3Y
84.8% | 53.6%
Increased
25 Years
Financials (TTM | estimate)
Revenue
$92.1b | $94.7b
EBITDA
$32.3b | $35.1b
EBIT
$24.9b | $30.9b
Net Income
$25.1b | $26.4b
Free Cash Flow
$19.6b
Growth (TTM | estimate)
Revenue
5.1% | 6.6%
EBITDA
2.5% | 13.7%
EBIT
2.9% | 31.6%
Net Income
71.1% | 87.7%
Free Cash Flow
-5.5%
Margin (TTM | estimate)
Gross
68.1%
EBITDA
35.0% | 37.0%
EBIT
27.0%
Net
27.3% | 27.9%
Free Cash Flow
21.3%
Financial Health
Equity Ratio
39.7%
Return on Equity
19.7%
ROCE
17.5%
ROIC
12.2%
Debt/Equity
0.6
More
EPS
$10.4
FCF per Share
$8.1
Short interest
0.9%
Employees
138k
Rev per Employee
$640.0k
Show more

Create a Free Account to create an Johnson & Johnson alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Johnson & Johnson Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Johnson & Johnson forecast:

18x Buy
58%
13x Hold
42%

Analyst Opinions

31 Analysts have issued a Johnson & Johnson forecast:

Buy
58%
Hold
42%

Financial data from Johnson & Johnson

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
92,149 92,149
5% 5%
100%
- Direct Costs 29,361 29,361
9% 9%
32%
62,788 62,788
4% 4%
68%
- Selling and Administrative Expenses 23,376 23,376
5% 5%
25%
- Research and Development Expense 15,711 15,711
4% 4%
17%
32,265 32,265
3% 3%
35%
- Depreciation and Amortization 7,388 7,388
1% 1%
8%
EBIT (Operating Income) EBIT 24,877 24,877
3% 3%
27%
Net Profit 25,119 25,119
71% 71%
27%

In millions USD.

Don't miss a Thing! We will send you all news about Johnson & Johnson directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Johnson & Johnson Stock News

Positive
24/7 Wall Street
2 days ago
At 24/7 Wall St., we have focused on dividend stocks for over 15 years because, despite the stock market's ups and downs, many people need solid passive income streams to supplement their income from employment or other sources.
Negative
Seeking Alpha
2 days ago
Johnson & Johnson's latest dividend declaration translates into an annual growth rate of 4.47%. This is the lowest level in at least 10 years, signaling ongoing growth pressures. Mixed Q3 earnings results and Q4 outlook suggest profit headwinds and rising payout ratios, further limiting room for future dividend increases.
Neutral
PRNewsWire
3 days ago
Phase 3 AQUILA study showed DARZALEX FASPRO® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring   Landmark approval supports earlier intervention and disease interception of multiple myeloma for the first time  HORSHAM, Pa. , Nov. 6, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced the U.S. Food and Drug...
More Johnson & Johnson News

Company Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Head office United States
CEO Joaquin Duato
Employees 138,100
Founded 1887
Website www.jnj.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today